2/19/2019 – RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea in Australia, New Zealand and Southeast Asia February 19, 2019j3ff1 Read More
1/3/2019 – RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors January 3, 2019j3ff1 Read More
12/10/2018 – RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit,December 10 – 12, 2018 December 10, 2018j3ff1 Read More
09/10/18 – RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc. September 10, 2018j3ff1 Read More
07/25/2018 – RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data: Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain July 25, 2018j3ff1 Read More
06/19/2018 – RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso June 19, 2018j3ff1 Read More
06/19/2018 – RespireRx Pharmaceuticals Inc. Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc. June 19, 2018j3ff1 Read More
RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase 2018 January 8, 2018j3ff1 Read More
RespireRx Pharmaceuticals Publishes Scientific Evidence Demonstrating CX717 Neurobiological Safety December 18, 2017j3ff1 Read More
